StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
October 30, 2024 6:10 AM
Goldman Sachs analyst Corinne Jenkins reiterated a Sell rating and $28.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Axonis Therapeutics Announces $115 Million Series A Financing
October 30, 2024 6:00 AM
Form 424B7 Harmony Biosciences Hold
October 29, 2024 5:28 PM
Harmony Biosciences (HRMY) Commences 8M Share Offering by Selling Stockholders
October 29, 2024 5:15 PM
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
October 29, 2024 5:15 PM
Form 144 Harmony Biosciences Hold Filed by: Dierks Jeffrey
October 29, 2024 4:23 PM
Form 10-Q Harmony Biosciences Hold For: Sep 30
October 29, 2024 8:01 AM
Form 8-K Harmony Biosciences Hold For: Oct 29
October 29, 2024 7:50 AM
Harmony Biosciences (HRMY) Tops Q3 EPS by 12c, provides guidance
October 29, 2024 7:31 AM
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
October 29, 2024 7:30 AM
